MGNX (Macrogenics) Valuation Rank


MGNX Macrogenics Inc MGNX
47 GF Score
Price $4.47
GF Value $4.06
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Macrogenics Valuation Rank Related Terms

MGNX
47GF Score
Macrogenics Inc MGNX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Macrogenics (MGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of $4.47 is trading 10.1% above its estimated GF Value™ of $4.06. GuruFocus considers Macrogenics to be Fairly Valued.

Key valuation signals for MGNX:

  • Valuation Rank:
  • GF Value™: $4.06 vs. price of $4.47 (10.1% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges M55:Germany
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score

Get the complete analysis for MGNX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.47
Price
$4.06
GF Value